Age | 20–24 | 25–29 | 30–34 | 35–39 | 40–44 | 45–49 | 50–54 | 55–59 | 60+ | Total |
---|---|---|---|---|---|---|---|---|---|---|
N participants (%) | 629 (11.8) | 486 (9.1) | 513 (9.6) | 577 (10.8) | 691 (13.0) | 853 (16.0) | 831 (15.6) | 593 (11.1) | 145 (2.7) | 5318 (100) |
Cytology | ||||||||||
BL (%) | 46 (0.7) | 17 (3.5) | 15 (2.9) | 12 (2.0) | 10 (1.4) | 17 (2.0) | 5 (0.6) | 3 (0.5) | 0 (0.0) | 125 (2.3) |
LG (%) | 31 (0.5) | 13 (2.7) | 10 (1.9) | 4 (0.6) | 8 (1.2) | 4 (0.4) | 1 (0.1) | 3 (0.5) | 0 (0.0) | 74 (1.4) |
HG* (%) | 10 (1.5) | 17 (3.4) | 12 (2.3) | 9 (1.5) | 5 (0.7) | 4 (0.4) | 1 (0.1) | 3 (0.5) | 1 (0.6) | 62 (1.1) |
Unsatisfactory (%)† | 3 (0.4) | 9 (1.8) | 8 (1.5) | 7 (1.2) | 14 (2.0) | 17 (1.9) | 25 (3.0) | 30 (5.0) | 10 (6.8) | 123 (2.3) |
Histology | N (%) | |||||||||
Cancer | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 3 (0.05) |
CIN3 | 14 | 20‡ | 10 | 8 | 5 | 7 | 1 | 2 | 1 | 68 (1.2) |
CIN2 | 13 | 19 | 9 | 8 | 6 | 4 | 0 | 0 | 0 | 59 (1.1)§ |
CIN2+ (%) | 27 (4.3%) | 39 (8%) | 21 (4.1%) | 16 (2.8%) | 12 (1.7%) | 11 (1.3%) | 1 (0.1%) | 2 (0.3%) | 1 (0.7%) | 130 (2.4) |
In total, 222 colposcopies were performed (137 due to abnormal cytology and 85 due to PaVDaG protocol).
*Includes glandular abnormalities (n=6).
†Linear trend in unsatisfactory cytology samples with age p<0.001.
‡Includes GCIN3 (n=2).
§Two of these CIN2 cases had failed cervical HPV tests, so they feature only in the sensitivity/specificity calculations for cytology—as they were in the BA/LG and HG groups of patients
BL, borderline abnormality; CIN2+, cervical intraepithelial neoplasia (grade 2 or 3 or cancer); GCIN, glandular cervical intraepithelial neoplasia; HG, high-grade dyskaryosis; HPV, human papillomavirus; LG, low-grade dyskaryosis; PaVDaG, Papillomavirus Dumfries and Galloway.